Literature DB >> 2943525

"Two-route chemotherapy" using high-dose intra-arterial neocarzinostatin and systemic tiopronin, its antidote, for rat limb tumor.

Y Iwamoto, T Kuroiwa, K Aoki, T Baba.   

Abstract

We studied the effect of "two-route chemotherapy" (TRC) with intra-arterial (IA) neocarzinostatin (NCS) and IV N-(2-mercaptopropionyl)-glycine (tiopronin), its antidote, on rat limb tumors. Chemotherapy experiments were carried out on day 9 after the inoculation of 10(6) syngeneic transitional carcinoma cells into the hind limb in female Wistar King A rats. In the group given TRC, 3500 units/kg NCS and 800 mg/kg tiopronin were given via the femoral artery and the femoral vein, respectively. The antitumor effect was evaluated by the tumor weight on day 12 after the treatment. Compared with the weight of tumors in untreated controls, TRC reduced tumor weight to one-tenth, while 700 units/kg IA NCS alone reduced tumor weight to one-third and 700 units/kg systemic NCS alone reduced tumor weight to three-fourths of the control weight. In the group given TRC, WBC and nucleated bone marrow cells were completely protected and loss of body weight was slight.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943525     DOI: 10.1007/bf00256693

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report.

Authors:  C T KLOPP; T C ALFORD; J BATEMAN; G N BERRY; T WINSHIP
Journal:  Ann Surg       Date:  1950-10       Impact factor: 12.969

2.  Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration.

Authors:  S Sakamoto; J Ogata; K Ikegami; H Maeda
Journal:  Eur J Cancer       Date:  1980-01       Impact factor: 9.162

3.  Effective combination of anticancer drug with its antidote for chemotherapy of hepatic metastasis.

Authors:  T Baba; K Nishikawa
Journal:  Gan       Date:  1980-02

4.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.

Authors:  S B Howell; R Taetle
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

5.  Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits.

Authors:  Y Iwamoto; T Kawano; M Ishizawa; K Aoki; T Kuroiwa; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  "Two-route chemotherapy" using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice.

Authors:  Y Iwamoto; T Kawano; J Uozumi; K Aoki; T Baba
Journal:  Cancer Treat Rep       Date:  1984-11

7.  Binding of the nonprotein chromophore of neocarzinostatin to deoxyribonucleic acid.

Authors:  L F Povirk; I H Goldberg
Journal:  Biochemistry       Date:  1980-10-14       Impact factor: 3.162

8.  [Screening for the antagonizing agents against lethal toxicity of neocarzinostatin. I. Inhibitory effects of various drugs on the toxicity of neocarzinostatin in vitro and in vivo].

Authors:  A Ito; Y Koide; I Haneda; K Toriyama; M Ouchi; T Matsumoto; T Baba
Journal:  Jpn J Antibiot       Date:  1985-01

Review 9.  Neocarzinostatin in cancer chemotherapy (review).

Authors:  H Maeda
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

10.  "Two route chemotherapy" using cis-diamminedichloro-platinum(II) and its antidote, sodium thiosulfate, for peritoneally disseminated cancer in rats.

Authors:  S Taniguchi; T Baba
Journal:  Gan       Date:  1982-06
View more
  2 in total

1.  Efficacy of two-route chemotherapy using intraperitoneal neocarzinostatin and its antidote, intravenous tiopronin, for peritoneally disseminated tumors in mice.

Authors:  K Hasuda; H Kobayashi; T Kuroiwa; K Aoki; S Taniguchi; T Baba
Journal:  Jpn J Cancer Res       Date:  1989-03

2.  Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.

Authors:  T Oda; H Yamamoto; T Miki; H Maeda
Journal:  Jpn J Cancer Res       Date:  1989-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.